Abstract
The oncogenic fusion protein p210 Bcr-Abl is causally associated with virtually all cases of chronic myelogenous leukemia. The wild-type Bcr product has several recognizable structural and functional motifs including a domain that contains guanine nucleotide exchange activity for Rho family GTPases (DH/PH domain). Although this domain is retained within p210 Bcr-Abl, it has no known signaling activities in vivo. Here we report that a fragment of Bcr that encodes the isolated DH/PH domain is a potent activator of the NF-κB transcription factor. Within the context of full length Bcr, this activity is regulated by proximal flanking sequences that suppress the DH/PH domain encoded guanine nucleotide exchange activity. NF-κB activation by Bcr is not mediated by nuclear translocation, but rather by p38 mitogen-activated protein kinase (MAPK)-dependent modification of the RelA/p65 transactivation domain. Although we were able to demonstrate that Bcr can function as an exchange factor for Cdc42 in vivo, NF-κB activation appears to occur via a Cdc42-independent mechanism. These studies constitute direct evidence that the Bcr RhoGEF domain can function in vivo, and identify a new signaling activity that may contribute to the transforming potential of p210 Bcr-Abl.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aghazadeh B, Lowry WE, Huang XY, Rosen MK . 2000 Cell 102: 625–633
Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K . 1997 Science 275: 1308–1311
Bergmann M, Hart L, Lindsay M, Barnes PJ, Newton R . 1998 J. Biol. Chem. 273: 6607–6610
Bi F, Debreceni B, Zhu K, Salani B, Eva A, Zheng Y . 2001 Mol. Cell. Biol. 21: 1463–1474
Bonnard M, Mirtsos C, Suzuki S, Graham K, Huang J, Ng M, Itie A, Wakeham A, Shahinian A, Henzel WJ, Elia AJ, Shillinglaw W, Mak TW, Cao Z, Yeh WC . 2000 EMBO J. 19: 4976–4985
Chan LC, Karhi KK, Rayter SI, Heisterkamp N, Eridani S, Powles R, Lawler SD, Groffen J, Foulkes JG, Greaves MF, Wiedenmann LM . 1987 Nature 325: 635–637
Chuang TH, Xu X, Kaartinen V, Heisterkamp N, Groffen J, Bokoch GM . 1995 Proc. Natl. Acad. Sci. USA 92: 10282–10286
Clark CJ, Cox AD, Graham SM, Der CJ . 1995 Methods Enzymol. 255: 395–412
Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, Crist W, Rovera G, Smith SD, Witte ON . 1988 Science 239: 775–777
Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T, Gutkind JS . 1995 Cell 81: 1137–1146
Diekmann D, Brill S, Garrett MD, Totty N, Hsuan J, Monfries C, Hall C, Lim L, Hall A . 1991 Nature 351: 400–402
Fainstein E, Marcelle C, Rosner A, Canaani E, Gale RP, Dreazen O, Smith SD, Croce CM . 1987 Nature 330: 386–388
Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin Jr AS . 1997 J. Biol Chem. 272: 24113–24116
Galang CK, Garcia-Ramirez J, Solski PA, Westwick JK, Der CJ, Neznanov NN, Oshima RG, Hauser CA . 1996 J. Biol. Chem. 271: 7992–7998
Glaven JA, Whitehead I, Bagrodia S, Kay R, Cerione RA . 1999 J. Biol. Chem. 274: 2279–2285
Habets GG, Scholtes EH, Zuydgeest D, van der Kammen RA, Stam JC, Berns A, Collard JG . 1994 Cell 77: 537–549
Hall A . 1994 Annu. Rev. Cell. Biol. 10: 31–54
Han J, Das B, Wei W, Van Aelst L, Mosteller RD, Khosravi-Far R, Westwick JK, Der CJ, Broek D . 1997 Mol. Cell. Biol. 17: 1346–1353
Hauser CA, Westwick JK, Quilliam LA . 1995 Methods Enzymol. 255: 412–426
Hill CS, Wynne J, Treisman R . 1995 Cell 81: 1159–1170
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR . 2000 Nature 406: 86–90
Horii Y, Beeler JF, Sakaguchi K, Tachibana M, Miki T . 1994 EMBO J. 13: 4776–4786
Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y, Narumiya S . 1997 FEBS Lett. 404: 118–124
Karin M . 1999 Oncogene 18: 6867–6874
Kin Y, Li G, Shibuya M, Maru Y . 2001 J. Biol. Chem. 276: 39462–39468
Konopka JB, Watanabe SM, Witte ON . 1984 Cell 37: 1035–1042
Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpas M, Trujillo JM, Blick M, Beran M, Gutterman JU . 1987 Nature 325: 631–635
Lali FV, Hunt AE, Turner SJ, Foxwell BM . 2000 J. Biol. Chem. 275: 7395–7402
Leung T, Chen XQ, Manser E, Lim L . 1996 Mol. Cell. Biol. 16: 5313–5327
Lugo TG, Pendergast AM, Muller AJ, Witte ON . 1990 Science 247: 1079–1082
Madrid LV, Mayo MW, Reuther JY, Baldwin Jr AS . 2001 J. Biol. Chem. 276: 18934–18940
Marinissen MJ, Chiariello M, Gutkind JS . 2001 Genes Dev. 15: 535–553
Maru Y . 2001 Int. J. Hematol. 73: 308–322
Maru Y, Kobayashi T, Tanaka K, Shibuya M . 1999 Biochem. Biophys. Res. Commun. 260: 309–312
Maru Y, Witte ON . 1991 Cell 67: 459–468
McWhirter JR, Galasso DL, Wang JY . 1993 Mol. Cell. Biol. 3: 7587–7595
Miki T, Smith CL, Long JE, Eva A, Fleming TP . 1993 Nature 362: 462–465
Minden A, Lin A, Claret FX, Abo A, Karin M . 1995 Cell 81: 1147–1157
Montaner S, Perona R, Saniger L, Lacal JC . 1998 J. Biol. Chem. 273: 12779–12785
Nobes CD, Hall A . 1995 Biochem. Soc. Trans. 23: 456–459
Olson MF, Ashworth A, Hall A . 1995 Science 269: 1270–1272
Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC . 1997 Genes Dev. 11: 463–475
Qiu RG, Abo A, McCormick F, Symons M . 1997 Mol. Cell. Biol. 17: 3449–3458
Reid T, Furuyashiki T, Ishizaki T, Watanabe G, Watanabe N, Fujisawa K, Morii N, Madaule P, Narumiya S . 1996 J. Biol. Chem. 271: 13556–13560
Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin Jr AS . 1998 Genes Dev. 12: 968–981
Ridley AJ . 1995 Curr. Opin. Genet. Dev. 5: 24–30
Rizo J, Sudhof TC . 1998 J. Biol. Chem. 273: 15879–15882
Ron D, Zannini M, Lewis M, Wickner RB, Hunt LT, Graziani G, Tronick SR, Aaronson SA, Eva A . 1991 New Biol. 3: 372–379
Sahai E, Ishizaki T, Narumiya S, Treisman R . 1999 Curr. Biol. 9: 136–145
Schmitz ML, Baeuerle PA . 1991 EMBO J. 10: 3805–3817
Sizemore N, Leung S, Stark GR . 1999 Mol. Cell. Biol. 19: 4798–4805
Skorski T, Wlodarski P, Daheron L, Salomoni P, Nieborowska-Skorska M, Majewski M, Wasik M, Calabretta B . 1998 Proc. Natl. Acad. Sci. USA 95: 11858–11862
Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y . 1994 Cell 77: 727–736
Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N . 1995 Blood 86: 4603–4611
Walker LC, Ganesan TS, Dhut S, Gibbons B, Lister TA, Rothbard J, Young BD . 1987 Nature 329: 851–853
Watanabe N, Kato T, Fujita A, Ishizaki T, Narumiya S . 1999 Nat. Cell. Biol. 1: 136–143
Wesselborg S, Bauer MK, Vogt M, Schmitz ML, Schulze-Osthoff K . 1997 J. Biol. Chem. 272: 12422–12429
Westwick JK, Lee RJ, Lambert QT, Symons M, Pestell RG, Der CJ, Whitehead IP . 1998 J. Biol. Chem. 273: 16739–16747
Whitehead I, Kirk H, Tognon C, Trigo-Gonzalez G, Kay R . 1995 J. Biol. Chem. 270: 18388–18395
Whitehead IP, Abe K, Gorski JL, Der CJ . 1998 Mol. Cell. Biol. 18: 4689–4697
Whitehead IP, Campbell S, Rossman KL, Der CJ . 1997 Biochim. Biophys. Acta 1332: F1–23
Whitehead IP, Lambert QT, Glaven JA, Abe K, Rossman KL, Mahon GM, Trzaskos JM, Kay R, Campbell SL, Der CJ . 1999 Mol. Cell. Biol. 19: 7759–7770
Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ . 1998 Oncogene 17: 1415–1438
Acknowledgements
This work was supported by Public Health Service grant CA-77493 (IP Whitehead) from the National Cancer Institute.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Korus, M., Mahon, G., Cheng, L. et al. p38 MAPK-mediated activation of NF-κB by the RhoGEF domain of Bcr. Oncogene 21, 4601–4612 (2002). https://doi.org/10.1038/sj.onc.1205678
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205678
Keywords
This article is cited by
-
The thrombopoietin/MPL axis is activated in the Gata1low mouse model of myelofibrosis and is associated with a defective RPS14 signature
Blood Cancer Journal (2017)
-
Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression
Leukemia (2013)
-
RhoA: A therapeutic target for chronic myeloid leukemia
Molecular Cancer (2012)
-
The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation
Oncogene (2008)
-
Inhibition of c-Jun NH2-terminal kinase or extracellular signal-regulated kinase improves lung injury
Respiratory Research (2004)